

RENERGEN LIMITED

Incorporated in the Republic of South Africa

(Registration number: 2014/195093/06)

JSE Share code: REN

A2X Share code: REN

ISIN: ZAE000202610

LEI: 378900B1512179F35A69

Australian Business Number (ABN): 93 998 352 675

ASX Share code: RLT

("Renergen" or "the Company")



CRYO-VACC LAUNCHES IN SOUTH AFRICA WITH WORKING PROTOTYPE

Helium and natural gas company Renergen is proud to announce the completion and successful operation of the Company's first Cryo-Vacc™ prototype, which is being presented to South African based media at its headquarters in Johannesburg, today at 10am SAST.

Cryo-Vacc™ was designed and patented by Renergen for efficient transport and storage of ultra-cold biologics for periods of up to 25 days or longer in transit, where access to an external power source is not possible. The Cryo-Vacc™ has a temperature range of -150 °C to 8°C, making it highly versatile for a range of vaccines.

Combined with best-in-class cold chain monitoring and asset tracking technology from Beyond Wireless Proprietary Limited ("Beyond"), a World Health Organisation Performance, Quality and Safety (PQS) certified remote temperature monitoring solution provider, the Cryo-Vacc™ can provide accurate temperature readings of the vaccines whilst in transit, as well as GPS tracking to ensure the custody chain can be audited.

Beyond is an Internet of Things (IoT) solutions provider, specialising in remote temperature monitoring and control, with a specific focus on the global public healthcare sector. Beyond has active deployments in over 70 countries and are proud to partner with numerous for-profit enterprises, Ministries of Health, as well as several non-governmental organisations including UNICEF, the World Health Organisation, the International Committee for the Red Cross, and the Pan American Health Organisation.

"Our mission is to improve human health, quality of life, and secure humanity's future by leveraging the power and reach of the Internet of Things (IoT). We believe that eradicating poverty, hunger and inequality starts with preventing disease. It's simple - healthy communities are happier, safer and more prosperous. We are proud to partner with Renergen on Cryo-Vacc™" said Ian Lester, founder and CEO, Beyond.

Cryo-Vacc™ is ideal for both air and ground transportation, utilising liquid nitrogen to transport by road and helium to transport by air. Aside from helium being only a fraction of the weight of nitrogen, significantly reducing its cost in airfreight, when used in Cryo-Vacc™ helium can

accommodate up to 12 times more vials per flight compared to other cryogenics based on current flight safety regulations.

With the recent release of the NDoH tender for the distribution of vaccines in South Africa, Renegeren has teamed up with local express courier partner, DPD Laser, which is part of The Laser Group and known for its last mile courier express capabilities and infrastructure throughout South Africa.

“DPD Laser has been proudly serving South Africa for over 30 years, and we are excited to bring our extensive coverage and best-in-breed, technology-driven delivery services to enable mission-critical vaccine distribution using Cryo-Vacc™” said Anton Visagie, CEO, DPD Laser.

Validation of the Cryo-Vacc™ in anticipated deployment situations will commence shortly, but Renegeren has already commenced discussions for the sale of units to logistics companies outside of the South African Development Community (SADC).

“Precise temperature control combined with a formidable hold time in transit, makes Cryo-Vacc™ a compelling asset in the transport of biologics, especially in the developing world. With a useful temperature range of over 150 °C, Cryo-Vacc™ is very versatile when compared to even standard refrigeration technology. Every Renegeren team member is truly proud to be associated with such an innovative product and we hope that Cryo-Vacc™ helps save many lives and restore some normality as the world builds herd immunity,” said Renegeren CEO Stefano Marani.



Renegeren CEO Stefano Marani, with the Cryo-Vacc™

Johannesburg
15 February 2021

Authorised by: Stefano Marani
Chief Executive Officer
Designated Advisor

PSG Capital



PSG CAPITAL

For South African investor inquiries, contact Renergen
info@renergen.co.za
+2710 045 6007

For South African media queries contact OwnAlchemy
Michael Rubenstein
+2782 903 7797
michael@ownalchemy.com

For Australian Investors & Media, contact Citadel-MAGNUS
Cameron Gilenko
0466 984 953

www.renergen.co.za